Pyxis Oncology to Host In-Person (NYC) and Virtual Investor Event on Wednesday, November 20, 2024, to Present Preliminary Data from the Phase 1 Dose Escalation Trial of PYX-201
Pyxis Oncology (Nasdaq: PYXS) announced an upcoming investor event on November 20, 2024, to present preliminary data from their Phase 1 clinical trial of PYX-201. The event will be held both in-person in New York City and virtually. The presentation will cover data from approximately 80 patients, including safety, preliminary efficacy, and pharmacokinetics results for PYX-201, a first-in-concept antibody-drug conjugate targeting Extradomain-B Fibronectin in solid tumors. Executive management will be joined by physician thought leaders Dr. Anthony Tolcher and Dr. Glenn Hanna to discuss the findings and future development plans.
Pyxis Oncology (Nasdaq: PYXS) ha annunciato un evento per investitori in programma per il 20 novembre 2024, in cui presenterà i dati preliminari del loro studio clinico di Fase 1 su PYX-201. L'evento si svolgerà sia in presenza a New York City che in forma virtuale. La presentazione coprirà dati da circa 80 pazienti, inclusi risultati di sicurezza, efficacia preliminare e farmacocinetica per PYX-201, un coniugato anticorpo-farmaco di prima generazione che mira alla Fibronectina Extradomain-B nei tumori solidi. I dirigenti aziendali saranno accompagnati dai medici opinion leader Dr. Anthony Tolcher e Dr. Glenn Hanna per discutere le scoperte e i piani di sviluppo futuri.
Pyxis Oncology (Nasdaq: PYXS) anunció un próximo evento para inversores el 20 de noviembre de 2024, para presentar datos preliminares de su ensayo clínico de Fase 1 sobre PYX-201. El evento se llevará a cabo tanto en persona en la ciudad de Nueva York como de manera virtual. La presentación abarcará datos de aproximadamente 80 pacientes, incluyendo resultados de seguridad, eficacia preliminar y farmacocinética para PYX-201, un conjugado anticuerpo-fármaco de primera vez que apunta a la Fibronectina Extradomain-B en tumores sólidos. La dirección ejecutiva se unirá a los líderes médicos Dr. Anthony Tolcher y Dr. Glenn Hanna para discutir los hallazgos y los planes de desarrollo futuros.
Pyxis Oncology (Nasdaq: PYXS)는 2024년 11월 20일에 투자자 이벤트를 개최하여 PYX-201의 1상 임상 시험의 초기 데이터를 발표한다고 발표했습니다. 이 이벤트는 뉴욕시에서 대면으로 진행되며, 가상 형식으로도 개최됩니다. 발표는 약 80명의 환자 데이터를 포함하여 PYX-201의 안전성, 초기 효능 및 약동학 결과를 다룰 것입니다. 이 약물은 고형 종양에서 Extradomain-B Fibronectin을 표적으로 하는 최초의 항체-약물 접합체입니다. 경영진은 의사 사상가인 Dr. Anthony Tolcher와 Dr. Glenn Hanna와 함께 연구 결과와 향후 개발 계획에 대해 논의할 예정입니다.
Pyxis Oncology (Nasdaq: PYXS) a annoncé un prochain événement pour investisseurs le 20 novembre 2024, au cours duquel des données préliminaires de leur essai clinique de Phase 1 sur PYX-201 seront présentées. L'événement se tiendra à la fois en personne à New York et virtuellement. La présentation portera sur des données provenant d'environ 80 patients, y compris des résultats de sécurité, d'efficacité préliminaire et de pharmacocinétique pour PYX-201, un conjugué anticorps-médicament innovant ciblant la Fibronectine Extradomain-B dans les tumeurs solides. La direction sera rejointe par des leaders d'opinion médicale, le Dr Anthony Tolcher et le Dr Glenn Hanna, pour discuter des résultats et des futurs plans de développement.
Pyxis Oncology (Nasdaq: PYXS) gab bekannt, dass am 20. November 2024 ein bevorstehendes Investoren-Event stattfinden wird, bei dem vorläufige Daten aus ihrer Phase-1-Studie zu PYX-201 präsentiert werden. Die Veranstaltung wird sowohl persönlich in New York City als auch virtuell stattfinden. Die Präsentation umfasst Daten von etwa 80 Patienten, einschließlich Sicherheitsdaten, vorläufiger Wirksamkeit und pharmakokinetischen Ergebnissen für PYX-201, ein erstmals in der Konzeptentwicklung befindliches Antikörper-Arzneimittel-Konjugat, das auf Extradomain-B Fibronectin bei soliden Tumoren abzielt. Die Geschäftsführung wird von den medizinischen Meinungsführern Dr. Anthony Tolcher und Dr. Glenn Hanna unterstützt, um die Ergebnisse und zukünftigen Entwicklungspläne zu erörtern.
- Phase 1 trial data presentation includes substantial patient pool (80 patients)
- Notable medical experts participating in data presentation
- None.
BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced that it will host an in-person and virtual investor event to discuss preliminary data from the ongoing Phase 1 clinical trial evaluating PYX-201 in multiple types of solid tumors. The event will be held on November 20, 2024, at 4:30 p.m. ET at Venue 42 by Convene, located at 5 Times Square in New York City. Virtual attendance is also available.
Pyxis Oncology’s executive management team will be joined by the following physician thought leaders to discuss preliminary data from the Phase 1 trial:
- Anthony Tolcher, MD, FRCPC, FACP, Founder and Chief Executive Officer, NEXT Oncology
- Glenn Hanna, MD, Director, Center for Cancer Therapeutic Innovation (Early Drug Development Program) and Center for Salivary and Rare Head and Neck Cancers at Dana-Farber Cancer Institute, Associate Professor of Medicine, Harvard Medical School
PYX-201, the Company’s lead clinical drug candidate, is a first-in-concept antibody-drug conjugate with a microtubule inhibitor payload that uniquely targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component within the tumor extra-cellular matrix. PYX-201 is being evaluated in an open-label, multicenter, Phase 1 dose escalation trial in patients with relapsed or refractory solid tumors. The data presentation will include insights into approximately 80 patients, including available safety, preliminary efficacy, pharmacokinetics (PK), and the plan for the next development phase.
Anyone interested in attending the live event in person or via the webcast should RSVP to pyxis.oncology.data.event.
A live webcast and replay of the event will be available on the Events & Presentations page in the Investor Relations section of Pyxis Oncology’s website, ir.pyxisoncology.com.
About Pyxis Oncology, Inc.
Pyxis Oncology, Inc. is a clinical stage company focused on defeating difficult-to-treat cancers. The company is efficiently building next generation therapeutics that hold the potential for mono and combination therapies. PYX-201, an antibody-drug conjugate (ADC) that uniquely targets EDB+FN, a non-cellular structural component of the tumor extra-cellular matrix, and PYX-106, a fully human Siglec-15-targeting antibody designed to block suppression of T-cell proliferation and function, are being evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors. Pyxis Oncology’s therapeutic candidates are designed to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Pyxis Oncology’s ADC and immuno-oncology (IO) programs employ novel and emerging strategies to target a broad range of solid tumors resistant to current standards of care. To learn more, visit www.pyxisoncology.com or follow us on Twitter and LinkedIn.
Forward Looking Statements
This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements, including regarding the plans, timing or outcome of current or future clinical trials are based on current assumptions and expectations of future events and trends, and are subject to inherent uncertainties, risks, and changes, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Factors that could cause or contribute to such differences include, but are not limited to, those identified herein, and those discussed in the section titled “Risk Factors” set forth in Part II, Item 1A. of the Company’s Quarterly Report on Form 10-Q filed with SEC on August 14, 2024, and our other filings, each of which is on file with the Securities and Exchange Commission. These risks are not exhaustive. New risk factors emerge from time to time, and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date hereof and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.
Pyxis Oncology Contact
Pamela Connealy
CFO and COO
ir@pyxisoncology.com
FAQ
When will Pyxis Oncology (PYXS) present Phase 1 data for PYX-201?
How many patients are included in the PYXS PYX-201 Phase 1 trial data?
What type of data will be presented at the Pyxis Oncology (PYXS) investor event?
What is PYX-201 targeting in Pyxis Oncology's (PYXS) clinical trial?
